aldafermin (NGM282) / NGM Biopharma 
Welcome,         Profile    Billing    Logout  
 19 Diseases   1 Trial   1 Trial   230 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
aldafermin (NGM282) / NGM Biopharma
ALPINE-PSC, NCT06654726: A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects with Primary Sclerosing Cholangitis.

Recruiting
2/3
300
US
aldafermin, Placebo
NGM Biopharmaceuticals, Inc
Primary Sclerosing Cholangitis
12/28
12/30
NCT04210245 / 2019-002341-38: Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Completed
2b
160
Europe, US, RoW
aldafermin, Placebo
NGM Biopharmaceuticals, Inc
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
01/23
02/23
NCT05130047: Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

Completed
2
30
US
Aldafermin, NGM282, Placebo
Michael Camilleri, MD, NGM Biopharmaceuticals, Inc
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption, Bile Acid Diarrhea, Bile Acid Malabsorption Syndrome Type II, Functional Diarrhea
11/22
11/22

Download Options